Rituximab for treatment of autoimmune hemolytic anemia.
Indian Pediatr
; 49(8): 672-4, 2012 Aug.
Article
em En
| MEDLINE
| ID: mdl-22962244
ABSTRACT
We report the successful use of rituximab as single treatment modality in a five-month-old boy with fulminant warm autoantibody autoimmune hemolytic anemia, resistant to standard treatment. On admission, laboratory tests showed a profound anemia with a hemoglobin of 2.6 g/dL. Indirect and direct antiglobulin tests were strongly positive, and nonspecific IgG autoantibodies were detected. Two days of intravenous corticosteroids (methylprednisolone 4mg/kg) and immunoglobulins (1g/kg) did not halt the hemolysis and the infant was severely transfusion-dependent. Rituximab 375mg/sq m weekly was given for 4 weeks, the hepatosplenomegaly gradually regressed, the lymphocytes normalized and he is free from hemolysis two years after treatment.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Anticorpos Monoclonais Murinos
/
Anemia Hemolítica Autoimune
Tipo de estudo:
Diagnostic_studies
Limite:
Humans
/
Infant
/
Male
Idioma:
En
Ano de publicação:
2012
Tipo de documento:
Article